|
Tropical Journal of Pharmaceutical Research
Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
ISSN: 1596-5996 EISSN: 1596-5996
Vol. 15, No. 6, 2016, pp. 1335-1339
|
Bioline Code: pr16177
Full paper language: English
Document type: Research Article
Document available free of charge
|
|
Tropical Journal of Pharmaceutical Research, Vol. 15, No. 6, 2016, pp. 1335-1339
en |
Clinical effect of intravenous thrombolysis combined with nicorandil therapy in patients with acute ST-segment elevation myocardial infarction
Yu1,, Shu-Hua; Li2*, Lin & Zhang2, Shen
Abstract
Purpose: To evaluate the effectiveness of intravenous thrombolysis in combination with nicorandil in
the treatment of acute ST-segment elevation myocardial infarction (STEMI).
Methods: Patients who developed acute STEMI and underwent intravenous thrombolysis in the
hospital were selected and divided into observation group (n = 128) and control group (n = 114).
Besides thrombolytic therapy, the observation group was also given 20 mg of nicorandil. The control
group received conventional thrombolytic therapy only. Clinical effects and rehabilitation of patients
were observed.
Results: Cardiac troponin I (cTNI) level of the observation group was 4.0 ± 1.5, 8.3 ± 2.8 and 9.8 ± 3.9
after 4, 12 and 24 h, respectively, which is much lower than 5.8 ± 1.4, 11.4 ± 2.7 and 13.2 ± 4.2 in the
control group (p < 0.05). ST-segment resolution of observation group was higher (44 ± 14, 52 ± 17, 69 ±
21 and 80 ± 18) % at different time points, compared with the control group (p < 0.05). The proportion of
patients with Curtis-Walker score > 3 points, and ventricular wall motion score (4.70 %; 1.38 ± 0.11) in
the observation group were both lower than those of the control group (21.00 %; 1.43 ± 0.15) (p < 0.05).
The difference in adverse cardiac events between the observation group (N = 6, 4.70 %) and control
group (N = 12, 10.50 %) was not statistically significant (p > 0.05)
Conclusion: Combining intravenous thrombolysis with nicorandil therapy can enhance myocardial
perfusion level, reduce myocardial damage, improve cardiac function and decrease risk of arrhythmia
for acute STEMI patients.
Keywords
ST-segment elevation; Myocardial infarction; Arrhythmia; Nicorandil; ST-segment; Thrombolytic therapy; Curtis-Walker score
|
|
© Copyright 2016 - Tropical Journal of Pharmaceutical Research Alternative site location: http://www.tjpr.org
|
|